{
    "info": {
        "nct_id": "NCT05002569",
        "official_title": "A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma",
        "inclusion_criteria": "* Must have been diagnosed with either Stage IIIA (> 1 mm tumor in lymph node)/B/C/D or Stage IV melanoma by American Joint Committee on Cancer (AJCC) v8 and have histologically confirmed melanoma that is completely surgically resected (free of disease) with negative margins in order to be eligible\n* Participants ≥ 18 years of age must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1. Adolescent participants between 12 and < 18 years of age must have a Lansky/Karnofsky performance score ≥ 80%\n* Complete resection must be performed within 90 days prior to randomization\n* All participants must have disease-free status documented by a complete physical examination within 14 days prior to randomization and imaging studies within 35 days prior to randomization\n* Tumor tissue must be provided for biomarker analyses\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
        "exclusion_criteria": "* History of ocular melanoma\n* Untreated/unresected CNS metastases or leptomeningeal metastases\n* Active, known, or suspected autoimmune disease\n* Participants with serious or uncontrolled medical disorder\n* Prior immunotherapy treatment for any prior malignancy: No prior immunotherapies are permitted\n* Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 4 weeks prior to screening\n* History of myocarditis, regardless of etiology.\n\nOther protocol-defined inclusion/exclusion criteria apply",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Complete resection must be performed within 90 days prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "Complete resection must be performed within 90 days prior to randomization",
                    "criterion": "complete resection",
                    "requirements": [
                        {
                            "requirement_type": "procedure_performed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time_since_procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 12 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 12 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tumor tissue must be provided for biomarker analyses",
            "criterions": [
                {
                    "exact_snippets": "Tumor tissue must be provided",
                    "criterion": "tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "for biomarker analyses",
                    "criterion": "biomarker analyses on tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "purpose",
                            "expected_value": "biomarker analyses"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All participants must have disease-free status documented by a complete physical examination within 14 days prior to randomization and imaging studies within 35 days prior to randomization",
            "criterions": [
                {
                    "exact_snippets": "disease-free status documented",
                    "criterion": "disease-free status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "complete physical examination within 14 days prior to randomization",
                    "criterion": "physical examination",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "imaging studies within 35 days prior to randomization",
                    "criterion": "imaging studies",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 35,
                                "unit": "days prior to randomization"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants ≥ 18 years of age must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1. Adolescent participants between 12 and < 18 years of age must have a Lansky/Karnofsky performance score ≥ 80%",
            "criterions": [
                {
                    "exact_snippets": "Participants ≥ 18 years of age ... must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "age group",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Adolescent participants between 12 and < 18 years of age ... must have a Lansky/Karnofsky performance score ≥ 80%",
                    "criterion": "Lansky/Karnofsky performance score",
                    "requirements": [
                        {
                            "requirement_type": "age group",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 12,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": "<",
                                        "value": 18,
                                        "unit": "years"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": ">=",
                                "value": 80,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have been diagnosed with either Stage IIIA (> 1 mm tumor in lymph node)/B/C/D or Stage IV melanoma by American Joint Committee on Cancer (AJCC) v8 and have histologically confirmed melanoma that is completely surgically resected (free of disease) with negative margins in order to be eligible",
            "criterions": [
                {
                    "exact_snippets": "diagnosed with either Stage IIIA (> 1 mm tumor in lymph node)/B/C/D or Stage IV melanoma by American Joint Committee on Cancer (AJCC) v8",
                    "criterion": "melanoma stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "Stage IIIA (> 1 mm tumor in lymph node)",
                                "Stage IIIB",
                                "Stage IIIC",
                                "Stage IIID",
                                "Stage IV"
                            ]
                        },
                        {
                            "requirement_type": "staging_system",
                            "expected_value": "AJCC v8"
                        }
                    ]
                },
                {
                    "exact_snippets": "histologically confirmed melanoma",
                    "criterion": "melanoma diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "histological confirmation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "completely surgically resected (free of disease) with negative margins",
                    "criterion": "surgical resection status",
                    "requirements": [
                        {
                            "requirement_type": "completeness of resection",
                            "expected_value": "completely resected"
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": "free of disease"
                        },
                        {
                            "requirement_type": "margin status",
                            "expected_value": "negative margins"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Prior immunotherapy treatment for any prior malignancy: No prior immunotherapies are permitted",
            "criterions": [
                {
                    "exact_snippets": "Prior immunotherapy treatment for any prior malignancy: No prior immunotherapies are permitted",
                    "criterion": "prior immunotherapy treatment for any prior malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Other protocol-defined inclusion/exclusion criteria apply",
            "criterions": [
                {
                    "exact_snippets": "Other protocol-defined inclusion/exclusion criteria apply",
                    "criterion": "other protocol-defined inclusion/exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 4 weeks prior to screening",
            "criterions": [
                {
                    "exact_snippets": "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection within 4 weeks prior to screening",
                    "criterion": "SARS-CoV-2 infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since infection",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to screening"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Untreated/unresected CNS metastases or leptomeningeal metastases",
            "criterions": [
                {
                    "exact_snippets": "Untreated/unresected CNS metastases",
                    "criterion": "CNS metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        },
                        {
                            "requirement_type": "resection status",
                            "expected_value": "unresected"
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal metastases",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of myocarditis, regardless of etiology.",
            "criterions": [
                {
                    "exact_snippets": "History of myocarditis, regardless of etiology.",
                    "criterion": "myocarditis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of ocular melanoma",
            "criterions": [
                {
                    "exact_snippets": "History of ocular melanoma",
                    "criterion": "ocular melanoma",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants with serious or uncontrolled medical disorder",
            "criterions": [
                {
                    "exact_snippets": "serious or uncontrolled medical disorder",
                    "criterion": "medical disorder",
                    "requirements": [
                        {
                            "requirement_type": "seriousness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active, known, or suspected autoimmune disease",
            "criterions": [
                {
                    "exact_snippets": "Active, known, or suspected autoimmune disease",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "active",
                                "known",
                                "suspected"
                            ]
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}